• Nanjing Leads Biolabs moved its Phase II study of Opamtistomig into an expansion stage for first-line esophageal squamous cell carcinoma.
• Safety run-in results have already been assessed, showing encouraging early activity with a favorable overall safety and tolerability profile.
• The expansion will run as a randomized head-to-head trial versus tislelizumab with chemotherapy, targeting a stronger first-line standard of care.
• Opamtistomig is being tested across 11 studies, supported by broad early signals without new technical data disclosed in this update.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608242225PRIMZONEFULLFEED9815425) on August 25, 2026, and is solely responsible for the information contained therein.